Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is ALXN's Inventory?

  Alexion Pharmaceuticals Inc ( ALXN ) |
2007 - 2021 (15 years)

Inventory is 
$2.9B (1Y +18.2% )

ALXN Stock Price & Inventory

Inventory for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Inventory

chevron_right 2021 $775.7M +13.8x
( +19.7% / year avg)
chevron_left 2007 $52.6M
vertical_align_top Peak $2.5B +47.0x
vertical_align_bottom Bottom $52.6M
arrow_drop_up # Up Years 14 14 of 15
years up.
arrow_drop_down # Down Years 1
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 2007 , or +3.26x faster than it's inventory over the same period.
  • If ALXN grows it's stock at the same rate as it's inventory (+19.7%/year) , it's stock price will grow +603% and hit $656.52 over the next 10 years.
  • ALXN's stock price has gone up 9 of the 14 years (+64%) it's inventory were also up.
  • ALXN Historical Inventory Table
    in $ million
    Year Inventory YoY % Change Stock Price YoY % Change (Stock Price)
    4/1/2021 $775 -69.2% $108.72 -9.3%
    4/1/2020 $2,521 24.4% $119.9 5.5%
    4/1/2019 $2,026 11.8% $113.68 -2.1%
    4/1/2018 $1,812 11.8% $116.13 18.5%
    4/1/2017 $1,622 77.5% $98.03 -30.4%
    4/1/2016 $913 11.2% $140.8 -21.9%
    4/1/2015 $821 60.0% $180.37 2.0%
    4/1/2014 $513 24.0% $176.8 91.9%
    4/1/2013 $414 15.6% $92.14 -0.8%
    4/1/2012 $358 23.6% $92.86 88.2%
    4/1/2011 $290 35.2% $49.34 81.5%
    4/1/2010 $214 15.6% $27.18 44.4%
    4/1/2009 $185 13.4% $18.83 27.0%
    4/1/2008 $163 211.4% $14.82 37.1%
    4/1/2007 $52 - $10.81 -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  • Inventory represents the company's raw materials, work-in-progress goods and finished goods. Depending on the company, the exact makeup of the inventory account will differ. For example, a manufacturing firm will carry a large number of raw materials, while a retail firm carries none. The makeup of a retailer's inventory typically consists of goods purchased from manufacturers and wholesalers.

    For more detailed definitions, please see Investopedia.